Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.60 |
| ▸ | CPB1 | P15086 | 1/20 | 0.60 |
| ▸ | CPA3 | P15088 | 1/20 | 0.60 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14542152 | 1.00 | CPA1 (0.60) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL750878 | 1.00 | CPA1 (0.60) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL9863278 | 0.98 | CPA1 (0.58) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL25955007 | 0.90 | CPA1 (0.55) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL13534695 | 0.89 | FFAR1 (0.55) | CPA1 | |
| SCHEMBL12052895 | 0.88 | FOLH1 (0.50) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL16691549 | 0.86 | ALPI (0.52) | CPA1CPB1CPA3CPB2NPC1 | |
| SCHEMBL10835297 | 0.86 | ALPI (0.52) | CPA1CPB1CPA3CPB2NPC1 | |
| SCHEMBL24897744 | 0.84 | ALDH1A1 (0.48) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL14032253 | 0.84 | TAAR1 (0.52) | CPA1ITGB3ITGB1ITGAVITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286909-A1 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | NOVEN PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-20170247688-A1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2017-08-31 | — | — | US | disclosed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286909-A1 | AMPHETAMINE CARBAMATE COMPOUNDS AND METHODS | CHAT, CES2, NAAA | CPA1 1994/4885CPB1 1213/4885CPA3 1196/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | CPA1 81/4885CPB1 59/4885CPA3 16/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | CPA1 81/4885CPB1 59/4885CPA3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.